Evidence map›Paper›PMID 37915915›Full record

ArticleClinical kidney journal2023

Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in patients on kidney replacement therapy: observational study using the OpenSAFELY-UKRR and SRR databases.

Bang Zheng, Jacqueline Campbell, Edward J Carr, John Tazare, Linda Nab, Viyaasan Mahalingasivam, Amir Mehrkar, Shalini Santhakumaran, Retha Steenkamp, Fiona Loud and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical kidney journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 8 institutions in 1 country.

Bang ZhengLondon School of Hygiene and Tropical Medicine, Keppel Street, London, UK.ORCID https://orcid.org/0000-0003-1814-6692
Jacqueline CampbellScottish Renal Registry, Scottish Health Audits, Public Health Scotland, Glasgow, UK.
Edward J CarrFrancis Crick Institute, London, UK.
John TazareLondon School of Hygiene and Tropical Medicine, Keppel Street, London, UK.
Linda NabBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Viyaasan MahalingasivamLondon School of Hygiene and Tropical Medicine, Keppel Street, London, UK.
Amir MehrkarBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Shalini SanthakumaranUK Renal Registry, Bristol, UK.
Retha SteenkampUK Renal Registry, Bristol, UK.
Fiona LoudKidney Care UK, Alton, UK.
Susan LyonPatient Council, UK Kidney Association, Bristol, UK.
Miranda ScanlonKidney Research UK, Peterborough, UK.
William J HulmeBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Amelia C A GreenBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Helen J CurtisBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Louis FisherBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Edward ParkerLondon School of Hygiene and Tropical Medicine, Keppel Street, London, UK.
Ben GoldacreBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.ORCID https://orcid.org/0000-0002-5127-4728
Ian DouglasLondon School of Hygiene and Tropical Medicine, Keppel Street, London, UK.
Stephen EvansLondon School of Hygiene and Tropical Medicine, Keppel Street, London, UK.
Brian MacKennaBennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Samira BellScottish Renal Registry, Scottish Health Audits, Public Health Scotland, Glasgow, UK.
Laurie A TomlinsonLondon School of Hygiene and Tropical Medicine, Keppel Street, London, UK.ORCID https://orcid.org/0000-0001-8848-9493
Dorothea NitschLondon School of Hygiene and Tropical Medicine, Keppel Street, London, UK.
OpenSAFELY Collaborative and LH&W NCS (or CONVALESCENCE) Collaborative
University of London · GBUniversity of Oxford · GBKidney Care UK · GBRenal Association · GBKidney Research UK · GBPublic Health Scotland · GBThe Francis Crick Institute · GBUniversity of Dundee · GB

Funding

Medical Research Council MC_PC_20030Medical Research Council MC_PC_20051Medical Research Council MC_PC_20059Wellcome Trust
6 · The paper itself

Abstract

Background: Due to limited inclusion of patients on kidney replacement therapy (KRT) in clinical trials, the effectiveness of coronavirus disease 2019 (COVID-19) therapies in this population remains unclear. We sought to address this by comparing the effectiveness of sotrovimab against molnupiravir, two commonly used treatments for non-hospitalised KRT patients with COVID-19 in the UK. Methods: With the approval of National Health Service England, we used routine clinical data from 24 million patients in England within the OpenSAFELY-TPP platform linked to the UK Renal Registry (UKRR) to identify patients on KRT. A Cox proportional hazards model was used to estimate hazard ratios (HRs) of sotrovimab versus molnupiravir with regards to COVID-19-related hospitalisations or deaths in the subsequent 28 days. We also conducted a complementary analysis using data from the Scottish Renal Registry (SRR). Results: Among the 2367 kidney patients treated with sotrovimab ( Conclusions: In routine care of non-hospitalised patients with COVID-19 on KRT, sotrovimab was associated with a lower risk of severe COVID-19 outcomes compared with molnupiravir during Omicron waves.

Indexed as

cohort studiescomparative effectiveness researchCOVID-19renal replacement therapy

Identifiers

PMID37915915
PMCPMC10616487
OpenAlexW4385691151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.